Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging
Abstract
:Simple Summary
Abstract
1. Introduction
2. Glycans
2.1. Background
2.2. Aberrant Glycosylation in Cancer
2.3. Imaging of sTn
2.4. Imaging of sLea/CA19-9
2.5. Glycan Imaging in the Clinic
3. Gangliosides
3.1. Background
3.2. Imaging of GD2
3.3. Ganglioside-Based Nerve Imaging
4. Proteoglycans
4.1. Background
4.2. Imaging of Syndecan-1
4.3. Imaging of Glypican-3
5. Mucins
5.1. Background
5.2. Imaging of MUC1
5.3. Imaging of MUC1/MUC5AC:PAM4-Based Systems
5.4. Imaging of MUC16
6. Targeting the Glycome: Opportunities and Challenges
7. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Fass, L. Imaging and cancer: A review. Mol. Oncol. 2008, 2, 115–152. [Google Scholar] [CrossRef]
- Weissleder, R. Molecular imaging in cancer. Science 2006, 312, 1168–1171. [Google Scholar] [CrossRef] [Green Version]
- Frangioni, J.V. New technologies for human cancer imaging. J. Clin. Oncol. 2008, 26, 4012–4021. [Google Scholar] [CrossRef] [PubMed]
- Munkley, J.; Elliott, D.J. Hallmarks of glycosylation in cancer. Oncotarget 2016, 7, 35478–35489. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, C.H. Protein glycosylation: New challenges and opportunities. J. Org. Chem. 2005, 70, 4219–4225. [Google Scholar] [CrossRef] [PubMed]
- Varki, A.; Kornfeld, S. Historical background and overview. In Essentials of Glycobiology; Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., Prestegard, J.H., Eds.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor: New York, NY, USA, 2015; pp. 1–18. [Google Scholar] [CrossRef]
- Pinho, S.; Marcos, N.T.; Ferreira, B.; Carvalho, A.S.; Oliveira, M.J.; Santos-Silva, F.; Harduin-Lepers, A.; Reis, C.A. Biological significance of cancer-associated sialyl-Tn antigen: Modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 2007, 249, 157–170. [Google Scholar] [CrossRef]
- Munkley, J. The Role of Sialyl-Tn in Cancer. Int. J. Mol. Sci. 2016, 17, 275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blanas, A.; Sahasrabudhe, N.M.; Rodríguez, E.; van Kooyk, Y.; van Vliet, S.J. Fucosylated antigens in cancer: An alliance toward tumor progression, metastasis, and resistance to chemotherapy. Front Oncol. 2018, 8, 39. [Google Scholar] [CrossRef]
- Reily, C.; Stewart, T.J.; Renfrow, M.B.; Novak, J. Glycosylation in health and disease. Nat. Rev. Nephrol. 2019, 15, 346–366. [Google Scholar] [CrossRef]
- Sakuma, S.; Yu, J.Y.; Quang, T.; Hiwatari, K.; Kumagai, H.; Kao, S.; Holt, A.; Erskind, J.; McClure, R.; Siuta, M.; et al. Fluorescence-based endoscopic imaging of Thomsen-Friedenreich antigen to improve early detection of colorectal cancer. Int. J. Cancer 2015, 136, 1095–1103. [Google Scholar] [CrossRef] [Green Version]
- Kumar, S.R.; Gallazzi, F.A.; Quinn, T.P.; Deutscher, S.L. (64) Cu-labeled peptide for PET of breast carcinomas expressing the Thomsen-Friedenreich carbohydrate antigen. J. Nucl. Med. 2011, 52, 1819–1826. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coustets, M.; Ladurantie, C.; Bellard, E.; Prat, M.; Rols, M.P.; Ecochard, V.; Ferron, G.; Chabot, S.; Golzio, M.; Paquereau, L. Development of a near infrared protein nanoprobe targeting Thomsen-Friedenreich antigen for intraoperative detection of submillimeter nodules in an ovarian peritoneal carcinomatosis mouse model. Biomaterials 2020, 241, 119908. [Google Scholar] [CrossRef] [PubMed]
- Danussi, C.; Coslovi, A.; Campa, C.; Mucignat, M.T.; Spessotto, P.; Uggeri, F.; Paoletti, S.; Colombatti, A. A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction. Glycobiology 2009, 19, 1056–1067. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gong, L.; Ding, H.; Long, N.E.; Sullivan, B.J.; Martin, E.W., Jr.; Magliery, T.J.; Tweedle, M.F. A 3E8.scFv.Cys-IR800 conjugate targeting TAG-72 in an orthotopic colorectal cancer model. Mol. Imaging Biol. 2018, 20, 47–54. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zou, P.; Xu, S.; Povoski, S.P.; Wang, A.; Johnson, M.A.; Martin, E.W., Jr.; Subramaniam, V.; Xu, R.; Sun, D. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol. Pharm. 2009, 6, 428–440. [Google Scholar] [CrossRef] [Green Version]
- Zou, P.; Povoski, S.P.; Hall, N.C.; Carlton, M.M.; Hinkle, G.H.; Xu, R.X.; Mojzisik, C.M.; Johnson, M.A.; Knopp, M.V.; Martin, E.W., Jr.; et al. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: Preliminary results. World J. Surg. Oncol. 2010, 8, 65. [Google Scholar] [CrossRef] [Green Version]
- Knight, J.C.; Mosley, M.; Uyeda, H.T.; Cong, M.; Fan, F.; Faulkner, S.; Cornelissen, B. In vivo pretargeted imaging of HER2 and TAG-72 expression using the halotag enzyme. Mol. Pharm. 2017, 14, 2307–2313. [Google Scholar] [CrossRef]
- Chinn, P.C.; Morena, R.A.; Santoro, D.A.; Kazules, T.; Kashmiri, S.V.; Schlom, J.; Hanna, N.; Braslawsky, G. Pharmacokinetics and tumor localization of (111) in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biother. Radiopharm. 2006, 21, 106–116. [Google Scholar] [CrossRef]
- Rossin, R.; Läppchen, T.; van den Bosch, S.M.; Laforest, R.; Robillard, M.S. Diels-Alder reaction for tumor pretargeting: In vivo chemistry can boost tumor radiation dose compared with directly labeled antibody. J. Nucl. Med. 2013, 54, 1989–1995. [Google Scholar] [CrossRef] [Green Version]
- Rossin, R.; van Duijnhoven, S.M.J.; Läppchen, T.; van den Bosch, S.M.; Robillard, M.S. Trans-cyclooctene tag with improved properties for tumor pretargeting with the Diels–Alder reaction. Mol. Pharm. 2014, 11, 3090–3096. [Google Scholar] [CrossRef]
- Houvast, R.D.; Baart, V.M.; Bhairosingh, S.S.; Cordfunke, R.A.; Chua, J.X.; Vankemmelbeke, M.; Parsons, T.; Kuppen, P.J.K.; Durrant, L.G.; Vahrmeijer, A.L.; et al. Glycan-based near-infrared fluorescent (NIRF) imaging of gastrointestinal tumors: A preclinical proof-of-concept in vivo study. Mol. Imaging Biol. 2020. [Google Scholar] [CrossRef] [PubMed]
- McElroy, M.; Kaushal, S.; Luiken, G.A.; Talamini, M.A.; Moossa, A.R.; Hoffman, R.M.; Bouvet, M. Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation. World J. Surg. 2008, 32, 1057–1066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hiroshima, Y.; Maawy, A.; Zhang, Y.; Murakami, T.; Momiyama, M.; Mori, R.; Matsuyama, R.; Katz, M.H.; Fleming, J.B.; Chishima, T.; et al. Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combination with fluorescence-guided surgery with an anti-CA 19-9-conjugated fluorophore. PLoS ONE 2014, 9, e114310. [Google Scholar] [CrossRef] [PubMed]
- Girgis, M.D.; Kenanova, V.; Olafsen, T.; McCabe, K.E.; Wu, A.M.; Tomlinson, J.S. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J. Surg. Res. 2011, 170, 169–178. [Google Scholar] [CrossRef] [PubMed]
- Girgis, M.D.; Federman, N.; Rochefort, M.M.; McCabe, K.E.; Wu, A.M.; Nagy, J.O.; Denny, C.; Tomlinson, J.S. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. J. Surg. Res. 2013, 185, 45–55. [Google Scholar] [CrossRef] [Green Version]
- Escorcia, F.E.; Steckler, J.M.; Abdel-Atti, D.; Price, E.W.; Carlin, S.D.; Scholz, W.W.; Lewis, J.S.; Houghton, J.L.J.M.I. Biology. Tumor-specific Zr-89 immuno-PET imaging in a human bladder cancer model. Mol. Imaging Biol. 2018, 20, 808–815. [Google Scholar] [CrossRef] [Green Version]
- Houghton, J.L.; Abdel-Atti, D.; Scholz, W.W.; Lewis, J.S. Preloading with unlabeled CA19.9 targeted human monoclonal antibody leads to improved PET imaging with 89Zr-5B1. Mol. Pharm. 2017, 14, 908–915. [Google Scholar] [CrossRef]
- Houghton, J.L.; Zeglis, B.M.; Abdel-Atti, D.; Sawada, R.; Scholz, W.W.; Lewis, J.S. Pretargeted immuno-pet of pancreatic cancer: Overcoming circulating antigen and internalized antibody to reduce radiation doses. J. Nucl. Med. 2016, 57, 453–459. [Google Scholar] [CrossRef] [Green Version]
- Rainey, J.; Maffuid, P.; Scholz, W.W.; Ostrowski, J.; Jun, H.T.; Resnick, P.; Li, X.; Bahn, J.D.; Zimmerman, S.; Chen, K.; et al. Abstract 3036: PEGylated hyaluronidase increases tumor uptake of 89Zr-DFO-HuMab-5B1 (MVT-2163) in a CA19-9 positive hyaluronan-accumulating pancreatic cancer model. Cancer Res. 2018, 78, 3036. [Google Scholar] [CrossRef]
- Houghton, J.L.; Zeglis, B.M.; Abdel-Atti, D.; Aggeler, R.; Sawada, R.; Agnew, B.J.; Scholz, W.W.; Lewis, J.S. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proc. Natl. Acad. Sci. USA 2015, 112, 15850–15855. [Google Scholar] [CrossRef] [Green Version]
- Hirai, M.; Minematsu, H.; Kondo, N.; Oie, K.; Igarashi, K.; Yamazaki, N. Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: Application to in vivo bio-imaging. Biochem. Biophys. Res. Commun. 2007, 353, 553–558. [Google Scholar] [CrossRef] [PubMed]
- Lovqvist, A.; Humm, J.L.; Sheikh, A.; Finn, R.D.; Koziorowski, J.; Ruan, S.; Pentlow, K.S.; Jungbluth, A.; Welt, S.; Lee, F.T.; et al. PET imaging of (86) Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: Comparison between (86) Y and (111) in radiolabels. J. Nucl. Med. 2001, 42, 1281–1287. [Google Scholar] [PubMed]
- Tahtis, K.; Lee, F.T.; Smyth, F.E.; Power, B.E.; Renner, C.; Brechbiel, M.W.; Old, L.J.; Hudson, P.J.; Scott, A.M. Biodistribution properties of (111) indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab’) (2) constructs in a breast carcinoma xenograft model. Clin. Cancer Res. 2001, 7, 1061–1072. [Google Scholar] [PubMed]
- Wellens, L.M.; Deken, M.M.; Sier, C.F.M.; Johnson, H.R.; de la Jara Ortiz, F.; Bhairosingh, S.S.; Houvast, R.D.; Kholosy, W.M.; Baart, V.M.; Pieters, A.; et al. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma. Sci. Rep. 2020, 10, 17667. [Google Scholar] [CrossRef]
- Vavere, A.L.; Butch, E.R.; Dearling, J.L.; Packard, A.B.; Navid, F.; Shulkin, B.L.; Barfield, R.C.; Snyder, S.E. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. J. Nucl. Med. 2012, 53, 1772–1778. [Google Scholar] [CrossRef] [Green Version]
- Butch, E.R.; Mead, P.E.; Amador Diaz, V.; Tillman, H.; Stewart, E.; Mishra, J.K.; Kim, J.; Bahrami, A.; Dearling, J.L.J.; Packard, A.B.; et al. Positron emission tomography detects in vivo expression of disialoganglioside GD2 in mouse models of primary and metastatic osteosarcoma. Cancer Res. 2019, 79, 3112–3124. [Google Scholar] [CrossRef] [Green Version]
- Kimbrough, C.W.; Hudson, S.; Khanal, A.; Egger, M.E.; McNally, L.R. Orthotopic pancreatic tumors detected by optoacoustic tomography using Syndecan-1. J. Surg. Res. 2015, 193, 246–254. [Google Scholar] [CrossRef] [Green Version]
- Bailly, C.; Gouard, S.; Lacombe, M.; Remaud-Le Saëc, P.; Chalopin, B.; Bourgeois, M.; Chouin, N.; Tripier, R.; Halime, Z.; Haddad, F.; et al. Comparison of Immuno-PET of CD138 and PET imaging with (64) CuCl (2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma. Oncotarget 2018, 9, 9061–9072. [Google Scholar] [CrossRef]
- Huang, X.; Fan, C.; Zhu, H.; Le, W.; Cui, S.; Chen, X.; Li, W.; Zhang, F.; Huang, Y.; Sh, D.; et al. Glypican-1-antibody-conjugated Gd-Au nanoclusters for FI/MRI dual-modal targeted detection of pancreatic cancer. Int. J. Nanomed. 2018, 13, 2585–2599. [Google Scholar] [CrossRef] [Green Version]
- Li, W.; Xiao, X.; Li, X.; Xu, Y.; Ma, L.; Guo, L.; Yan, C.; Wu, Y. Detecting GPC3-expressing hepatocellular carcinoma with L5 peptide-guided pretargeting approach: In vitro and in vivo MR imaging experiments. Contrast Media Mol. Imaging 2018, 2018, 5–13. [Google Scholar] [CrossRef] [Green Version]
- Zhu, D.; Qin, Y.; Wang, J.; Zhang, L.; Zou, S.; Zhu, X.; Zhu, L. Novel glypican-3-binding peptide for in vivo hepatocellular carcinoma fluorescent imaging. Bioconjug. Chem. 2016, 27, 831–839. [Google Scholar] [CrossRef] [PubMed]
- Sham, J.G.; Kievit, F.M.; Grierson, J.R.; Miyaoka, R.S.; Yeh, M.M.; Zhang, M.; Yeung, R.S.; Minoshima, S.; Park, J.O. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J. Nucl. Med. 2014, 55, 799–804. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sham, J.G.; Kievit, F.M.; Grierson, J.R.; Chiarelli, P.A.; Miyaoka, R.S.; Zhang, M.; Yeung, R.S.; Minoshima, S.; Park, J.O. Glypican-3-targeting F(ab’)2 for 89Zr PET of hepatocellular carcinoma. J. Nucl. Med. 2014, 55, 2032–2037. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, H.; Richardson, R.; Talebloo, N.; Mukherjee, P.; Wang, P.; Moore, A. uMUC1-targeting magnetic resonance imaging of therapeutic response in an orthotropic mouse model of colon cancer. Mol. Imag. Biol. 2019, 21, 852–860. [Google Scholar] [CrossRef]
- Ghosh, S.K.; Uchida, M.; Yoo, B.; Ross, A.W.; Gendler, S.J.; Gong, J.; Moore, A.; Medarova, Z. Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model. Int. J. Cancer 2013, 132, 1860–1867. [Google Scholar] [CrossRef]
- Wang, P.; Yoo, B.; Sherman, S.; Mukherjee, P.; Ross, A.; Pantazopoulos, P.; Petkova, V.; Farrar, C.; Medarova, Z.; Moore, A. Predictive imaging of chemotherapeutic response in a transgenic mouse model of pancreatic cancer. Int. J. Cancer 2016, 139, 712–718. [Google Scholar] [CrossRef]
- Moore, A.; Medarova, Z.; Potthast, A.; Dai, G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 2004, 64, 1821–1827. [Google Scholar] [CrossRef] [Green Version]
- Park, J.Y.; Hiroshima, Y.; Lee, J.Y.; Maawy, A.A.; Hoffman, R.M.; Bouvet, M. MUC1 Selectively targets human pancreatic cancer in orthotopic nude mouse models. PLoS ONE 2015, 10, e0122100. [Google Scholar] [CrossRef]
- Wu, G.; Maharjan, S.; Kim, D.; Kim, J.N.; Park, B.K.; Koh, H.; Moon, K.; Lee, Y.; Kwon, H.-J. A novel monoclonal antibody targets mucin1 and attenuates growth in pancreatic cancer model. Int. J. Mol. Sci. 2018, 19, 2004. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Q.; Wang, F.; Wu, Y.-S.; Zhang, K.-K.; Lin, Y.; Zhu, X.-Q.; Lv, J.-Q.; Lu, X.-S.; Zhang, X.-L.; Hu, Y.; et al. Dual-color labeled anti-mucin 1 antibody for imaging of ovarian cancer: A preliminary animal study. Oncol. Lett. 2015, 9, 1231–1235. [Google Scholar] [CrossRef] [Green Version]
- Chen, H.; Zhao, J.; Zhang, M.; Yang, H.; Ma, Y.; Gu, Y. MUC1 aptamer-based near-infrared fluorescence probes for tumor imaging. Mol. Imaging Biol. 2015, 17, 38–48. [Google Scholar] [CrossRef] [PubMed]
- Moore, L.J.; Roy, L.D.; Zhou, R.; Grover, P.; Wu, S.T.; Curry, J.M.; Dillon, L.M.; Puri, P.M.; Yazdanifar, M.; Puri, R.; et al. Antibody-guided in vivo imaging for early detection of mammary gland tumors. Transl. Oncol. 2016, 9, 295–305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stergiou, N.; Nagel, J.; Pektor, S.; Heimes, A.S.; Jäkel, J.; Brenner, W.; Schmidt, M.; Miederer, M.; Kunz, H.; Roesch, F.; et al. Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer. Int. J. Med. Sci. 2019, 16, 1188–1198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alirezapour, B.; Rasaee, M.J.; Jalilian, A.R.; Rajabifar, S.; Mohammadnejad, J.; Paknejad, M.; Maadi, E.; Moradkhani, S. Development of [(6)(4) Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging. Nucl. Med. Biol. 2016, 43, 73–80. [Google Scholar] [CrossRef] [PubMed]
- Salouti, M.; Rajabi, H.; Babaei, M.H.; Rasaee, M.J. Breast tumor targeting with (99 m) Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical. Nucl. Med. Biol. 2008, 35, 763–768. [Google Scholar] [CrossRef]
- Gold, D.V.; Goldenberg, D.M.; Karacay, H.; Rossi, E.A.; Chang, C.-H.; Cardillo, T.M.; McBride, W.J.; Sharkey, R.M. A Novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res. 2008, 68, 4819–4826. [Google Scholar] [CrossRef] [Green Version]
- Cardillo, T.M.; Karacay, H.; Goldenberg, D.M.; Yeldell, D.; Chang, C.-H.; Modrak, D.E.; Sharkey, R.M.; Gold, D.V. Improved targeting of pancreatic cancer. Clin. Cancer Res. 2004, 10, 3552. [Google Scholar] [CrossRef] [Green Version]
- Rossez, Y.; Burtea, C.; Laurent, S.; Gosset, P.; Leonard, R.; Gonzalez, W.; Ballet, S.; Raynal, I.; Rousseaux, O.; Dugue, T.; et al. Early detection of colonic dysplasia by magnetic resonance molecular imaging with a contrast agent raised against the colon cancer marker MUC5AC. Control Med. Mol. Imaging 2016, 11, 211–221. [Google Scholar] [CrossRef]
- Olson, M.T.; Wojtynek, N.E.; Talmon, G.A.; Caffrey, T.C.; Radhakrishnan, P.; Ly, Q.P.; Hollingsworth, M.A.; Mohs, A.M. Development of a MUC16-targeted near-infrared fluorescent antibody conjugate for intraoperative imaging of pancreatic cancer. Mol. Cancer Ther. 2020, 19, 1670–1681. [Google Scholar] [CrossRef]
- Sharma, S.K.; Wuest, M.; Wang, M.; Glubrecht, D.; Andrais, B.; Lapi, S.E.; Wuest, F. Immuno-PET of epithelial ovarian cancer: Harnessing the potential of CA125 for non-invasive imaging. EJNMMI Res. 2015, 4, 60. [Google Scholar] [CrossRef] [Green Version]
- Sharma, S.K.; Sevak, K.K.; Monette, S.; Carlin, S.D.; Knight, J.C.; Wuest, F.R.; Sala, E.; Zeglis, B.M.; Lewis, J.S. Preclinical 89Zr immuno-PET of high-grade serous ovarian cancer and lymph node metastasis. J. Nucl. Med. 2016, 57, 771–776. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharma, S.K.; Wuest, M.; Way, J.D.; Bouvet, V.R.; Wang, M.; Wuest, F.R. Synthesis and pre-clinical evaluation of an (18) F-labeled single-chain antibody fragment for PET imaging of epithelial ovarian cancer. Am. J. Nucl. Med. Mol. Imaging 2016, 6, 185–198. [Google Scholar] [PubMed]
- Cohen, A.M.; Martin, E.W., Jr.; Lavery, I.; Daly, J.; Sardi, A.; Aitken, D.; Bland, K.; Mojzisik, C.; Hinkle, G. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch. Surg. 1991, 126, 349–352. [Google Scholar] [CrossRef] [PubMed]
- Arnold, M.W.; Schneebaum, S.; Berens, A.; Petty, L.; Mojzisik, C.; Hinkle, G.; Martin, E.W., Jr. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann. Surg. 1992, 216, 627–632. [Google Scholar] [CrossRef] [PubMed]
- Nag, S.; Martinez-Monge, R.; Nieroda, C.; Martin, E., Jr. Radioimmunoguided-intraoperative radiation therapy in colorectal carcinoma: A new technique to precisely define the clinical target volume. Int. J. Radiat. Oncol. Biol. Phys. 1999, 44, 133–137. [Google Scholar] [CrossRef]
- Xiao, J.; Horst, S.; Hinkle, G.; Cao, X.; Kocak, E.; Fang, J.; Young, D.; Khazaeli, M.; Agnese, D.; Sun, D.; et al. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother. Radiopharm. 2005, 20, 16–26. [Google Scholar] [CrossRef] [PubMed]
- Fang, L.; Holford, N.H.G.; Hinkle, G.; Cao, X.; Xiao, J.J.; Bloomston, M.; Gibbs, S.; Al Saif, O.H.; Dalton, J.T.; Chan, K.K.; et al. Population pharmacokinetics of humanized monoclonal antibody HuCC49ΔCH2 and murine antibody CC49 in colorectal cancer patients. J. Clin. Pharm. 2007, 47, 227–237. [Google Scholar] [CrossRef]
- Lohrmann, C.; O’Reilly, E.M.; O’Donoghue, J.A.; Pandit-Taskar, N.; Carrasquillo, J.A.; Lyashchenko, S.K.; Ruan, S.; Teng, R.; Scholz, W.; Maffuid, P.W.; et al. Retooling a blood-based biomarker: Phase I assessment of the high-affinity CA19-9 antibody HuMab-5B1 for immuno-PET imaging of pancreatic cancer. Clin. Cancer Res. 2019, 25, 7014–7023. [Google Scholar] [CrossRef] [Green Version]
- Pai-Scherf, L.H.; Carrasquillo, J.A.; Paik, C.; Gansow, O.; Whatley, M.; Pearson, D.; Webber, K.; Hamilton, M.; Allegra, C.; Brechbiel, M.; et al. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3. Clin. Cancer Res. 2000, 6, 1720–1730. [Google Scholar]
- Quaia, E.; Krug, L.M.; Pandit-Taskar, N.; Nagel, A.; Reuter, V.E.; Humm, J.; Divgi, C. The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by (111) Indium-labeled humanized monoclonal antibody 3S193. Eur. J. Radiol. 2008, 67, 292–299. [Google Scholar] [CrossRef]
- Reuland, P.; Geiger, L.; Thelen, M.H.; Handgretinger, R.; Haase, B.; Müller-Schauenburg, W.; Niethammer, D.; Bares, R. Follow-up in neuroblastoma: Comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response. J. Pediatr. Hematol. Oncol. 2001, 23, 437–442. [Google Scholar] [CrossRef] [PubMed]
- Yeh, S.D.; Larson, S.M.; Burch, L.; Kushner, B.H.; Laquaglia, M.; Finn, R.; Cheung, N.K. Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J. Nucl. Med. 1991, 32, 769–776. [Google Scholar] [PubMed]
- Larson, S.M.; Pentlow, K.S.; Volkow, N.D.; Wolf, A.P.; Finn, R.D.; Lambrecht, R.M.; Graham, M.C.; Di Resta, G.; Bendriem, B.; Daghighian, F.; et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J. Nucl. Med. 1992, 33, 2020–2023. [Google Scholar] [PubMed]
- Hughes, O.; Perkins, A.; Frier, M.; Wastie, M.; Denton, G.; Price, M.; Denley, H.; Bishop, M. Imaging for staging bladder cancer: A clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. BJU Int. 2001, 87, 39–46. [Google Scholar] [CrossRef]
- Simms, M.; Perkins, A.; Price, M.; Scholfield, D.; Bishop, M. 99mTechnetium-C595 radioimmunoscintigraphy: A potential staging tool for bladder cancer. BJU Int. 2001, 88, 686–691. [Google Scholar] [CrossRef]
- Gulec, S.A.; Cohen, S.J.; Pennington, K.L.; Zuckier, L.S.; Hauke, R.J.; Horne, H.; Wegener, W.A.; Teoh, N.; Gold, D.V.; Sharkey, R.M.; et al. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: A phase I single-dose escalation trial. Clin. Cancer Res. 2011, 17, 4091–4100. [Google Scholar] [CrossRef] [Green Version]
- Li, M.; Song, L.; Qin, X. Glycan changes: Cancer metastasis and anti-cancer vaccines. J. Biosci. 2010, 35, 665–673. [Google Scholar] [CrossRef]
- Ohtsubo, K.; Marth, J.D. Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126, 855–867. [Google Scholar] [CrossRef] [Green Version]
- Varki, A. Biological roles of glycans. Glycobiology 2017, 27, 3–49. [Google Scholar] [CrossRef] [Green Version]
- Brockhausen, I. Pathways of O-glycan biosynthesis in cancer cells. Biochim. Biophys. Acta 1999, 1473, 67–95. [Google Scholar] [CrossRef]
- Vankemmelbeke, M.; Chua, J.X.; Durrant, L.G. Cancer cell associated glycans as targets for immunotherapy. Oncoimmunology 2016, 5, e1061177. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tivadar, S.T.; McIntosh, R.S.; Chua, J.X.; Moss, R.; Parsons, T.; Zaitoun, A.M.; Madhusudan, S.; Durrant, L.G.; Vankemmelbeke, M. Monoclonal antibody targeting sialyl-di-lewisa–Containing internalizing and non-internalizing glycoproteins with cancer immunotherapy development potential. Mol. Cancer Ther. 2019. [Google Scholar] [CrossRef] [Green Version]
- Julien, S.; Videira, P.A.; Delannoy, P. Sialyl-tn in cancer: (how) did we miss the target? Biomolecules 2012, 2, 435–466. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trinchera, M.; Aronica, A.; Dall’Olio, F. Selectin ligands Sialyl-Lewis a and Sialyl-Lewis x in gastrointestinal cancers. Biology 2017, 6, 16. [Google Scholar] [CrossRef] [PubMed]
- Prendergast, J.M.; Galvao da Silva, A.P.; Eavarone, D.A.; Ghaderi, D.; Zhang, M.; Brady, D.; Wicks, J.; DeSander, J.; Behrens, J.; Rueda, B.R. Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity. MAbs 2017, 9, 615–627. [Google Scholar] [CrossRef] [PubMed]
- Eavarone, D.A.; Al-Alem, L.; Lugovskoy, A.; Prendergast, J.M.; Nazer, R.I.; Stein, J.N.; Dransfield, D.T.; Behrens, J.; Rueda, B.R. Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma. PLoS ONE 2018, 13, e0201314. [Google Scholar] [CrossRef]
- Madjd, Z.; Parsons, T.; Watson, N.F.; Spendlove, I.; Ellis, I.; Durrant, L.G. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res. 2005, 7, 780–787. [Google Scholar] [CrossRef] [Green Version]
- Lottich, S.C.; Johnston, W.W.; Szpak, C.A.; Delong, E.R.; Thor, A.; Schlom, J. Tumor-associated antigen TAG-72: Correlation of expression in primary and metastatic breast carcinoma lesions. Breast Cancer Res. Treat 1985, 6, 49–56. [Google Scholar] [CrossRef]
- Loureiro, L.R.; Sousa, D.P.; Ferreira, D.; Chai, W.; Lima, L.; Pereira, C.; Lopes, C.B.; Correia, V.G.; Silva, L.M.; Li, C.; et al. Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids. Sci. Rep. 2018, 8, 12196. [Google Scholar] [CrossRef]
- Johnston, W.W.; Szpak, C.A.; Thor, A.; Schlom, J. Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3. Cancer Res. 1986, 46, 6462–6470. [Google Scholar]
- Kadota, A.; Masutani, M.; Takei, M.; Horie, T. Evaluation of expression of CD15 and sCD15 in non-small cell lung cancer. Int. J. Oncol. 1999, 15, 1081–1089. [Google Scholar] [CrossRef]
- Kajiwara, H.; Yasuda, M.; Kumaki, N.; Shibayama, T.; Osamura, Y. Expression of carbohydrate antigens (SSEA-1, sialyl-Lewis X, DU-PAN-2 and CA19-9) and E-selectin in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder. Tokai J. Exp. Clin. Med. 2005, 30, 177–182. [Google Scholar] [PubMed]
- Pochechueva, T.; Jacob, F.; Fedier, A.; Heinzelmann-Schwarz, V. Tumor-associated glycans and their role in gynecological cancers: Accelerating translational research by novel high-throughput approaches. Metabolites 2012, 2, 913–939. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Contessa, J.N.; Bhojani, M.S.; Freeze, H.H.; Rehemtulla, A.; Lawrence, T.S. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 2008, 68, 3803–3809. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yue, T.; Maupin, K.A.; Fallon, B.; Li, L.; Partyka, K.; Anderson, M.A.; Brenner, D.E.; Kaul, K.; Zeh, H.; Moser, A.J.; et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19–9 antigen on specific protein carriers. PLoS ONE 2011, 6, e29180. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pinto, R.; Carvalho, A.S.; Conze, T.; Magalhães, A.; Picco, G.; Burchell, J.M.; Taylor-Papadimitriou, J.; Reis, C.A.; Almeida, R.; Mandel, U.; et al. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J. Cell Mol. Med. 2012, 16, 1474–1484. [Google Scholar] [CrossRef] [PubMed]
- Sarrats, A.; Saldova, R.; Pla, E.; Fort, E.; Harvey, D.J.; Struwe, W.B.; de Llorens, R.; Rudd, P.M.; Peracaula, R. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin. Appl. 2010, 4, 432–448. [Google Scholar] [CrossRef] [PubMed]
- Balmaña, M.; Sarrats, A.; Llop, E.; Barrabés, S.; Saldova, R.; Ferri, M.J.; Figueras, J.; Fort, E.; de Llorens, R.; Rudd, P.M.; et al. Identification of potential pancreatic cancer serum markers: Increased sialyl-Lewis X on ceruloplasmin. Clin. Chimica Acta 2015, 442, 56–62. [Google Scholar] [CrossRef]
- Balmaña, M.; Duran, A.; Gomes, C.; Llop, E.; López-Martos, R.; Ortiz, M.R.; Barrabés, S.; Reis, C.A.; Peracaula, R. Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues. Int. J. Biol. Macromol. 2018, 112, 33–45. [Google Scholar] [CrossRef] [Green Version]
- Buffone, A.; Weaver, V.M. Don’t sugarcoat it: How glycocalyx composition influences cancer progression. J. Cell Biol. 2020, 219. [Google Scholar] [CrossRef]
- Burdick, M.D.; Harris, A.; Reid, C.J.; Iwamura, T.; Hollingsworth, M.A. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J. Biol. Chem. 1997, 272, 24198–24202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ozaki, H.; Matsuzaki, H.; Ando, H.; Kaji, H.; Nakanishi, H.; Ikehara, Y.; Narimatsu, H. Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin. Exper. Metastasis 2012, 29, 229–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, R.; Campbell, B.J.; Yu, L.G.; Fernig, D.G.; Milton, J.D.; Goodlad, R.A.; FitzGerald, A.J.; Rhodes, J.M. Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. Glycobiology 2001, 11, 587–592. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Loureiro, L.R.; Carrascal, M.A.; Barbas, A.; Ramalho, J.S.; Novo, C.; Delannoy, P.; Videira, P.A. Challenges in antibody development against Tn and Sialyl-Tn antigens. Biomolecules 2015, 5, 1783–1809. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rabu, C.; McIntosh, R.; Jurasova, Z.; Durrant, L. Glycans as targets for therapeutic antitumor antibodies. Future Oncol. 2012, 8, 943–960. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Walberg, L.A.; Ogata, S.; Itzkowitz, S.H.; Koganty, R.R.; Reddish, M.; Gandhi, S.S.; Longenecker, B.M.; Lloyd, K.O.; Livingston, P.O. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res. 1995, 55, 3364–3368. [Google Scholar]
- Sawada, R.; Sun, S.M.; Wu, X.; Hong, F.; Ragupathi, G.; Livingston, P.O.; Scholz, W.W. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin. Cancer Res. 2011, 17, 1024–1032. [Google Scholar] [CrossRef] [Green Version]
- Ferreira, I.G.; Carrascal, M.; Mineiro, A.G.; Bugalho, A.; Borralho, P.; Silva, Z.; Dall’olio, F.; Videira, P.A. Carcinoembryonic antigen is a sialyl Lewis x/a carrier and an E-selectin ligand in non-small cell lung cancer. Int. J. Oncol. 2019, 55, 1033–1048. [Google Scholar] [CrossRef] [PubMed]
- Gomes, C.; Almeida, A.; Barreira, A.; Calheiros, J.; Pinto, F.; Abrantes, R.; Costa, A.; Polonia, A.; Campos, D.; Osório, H.; et al. Carcinoembryonic antigen carrying SLe(X) as a new biomarker of more aggressive gastric carcinomas. Theranostics 2019, 9, 7431–7446. [Google Scholar] [CrossRef] [PubMed]
- Boogerd, L.S.F.; Hoogstins, C.E.S.; Schaap, D.P.; Kusters, M.; Handgraaf, H.J.M.; van der Valk, M.J.M.; Hilling, D.E.; Holman, F.A.; Peeters, K.; Mieog, J.S.D.; et al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: A dose-escalation pilot study. Lancet. Gastroenterol. Hepatol. 2018, 3, 181–191. [Google Scholar] [CrossRef]
- Noble, P.; Spendlove, I.; Harding, S.; Parsons, T.; Durrant, L.G. Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29. PLoS ONE 2013, 8, e54892. [Google Scholar] [CrossRef] [PubMed]
- Chua, J.X.; Vankemmelbeke, M.; McIntosh, R.S.; Clarke, P.A.; Moss, R.; Parsons, T.; Spendlove, I.; Zaitoun, A.M.; Madhusudan, S.; Durrant, L.G. Monoclonal antibodies targeting LecLex-related glycans with potent antitumor activity. Clin. Cancer Res. 2015, 21, 2963–2974. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shimomura, O.; Oda, T.; Tateno, H.; Ozawa, Y.; Kimura, S.; Sakashita, S.; Noguchi, M.; Hirabayashi, J.; Asashima, M.; Ohkohchi, N. A novel therapeutic strategy for pancreatic cancer: Targeting cell surface glycan using rBC2LC-N lectin-drug conjugate (LDC). Mol. Cancer Ther. 2018, 17, 183–195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mishra, A.; Behura, A.; Mawatwal, S.; Kumar, A.; Naik, L.; Mohanty, S.S.; Manna, D.; Dokania, P.; Mishra, A.; Patra, S.K.; et al. Structure-function and application of plant lectins in disease biology and immunity. Food Chem. Toxicol. 2019, 134, 110827. [Google Scholar] [CrossRef] [PubMed]
- Tiernan, J.P.; Ansari, I.; Hirst, N.A.; Millner, P.A.; Hughes, T.A.; Jayne, D.G. Intra-operative tumour detection and staging in colorectal cancer surgery. Colorectal Dis. 2012, 14, 510–520. [Google Scholar] [CrossRef]
- Ohmi, Y.; Kambe, M.; Ohkawa, Y.; Hamamura, K.; Tajima, O.; Takeuchi, R.; Furukawa, K.; Furukawa, K. Differential roles of gangliosides in malignant properties of melanomas. PLoS ONE 2018, 13, e0206881. [Google Scholar] [CrossRef] [Green Version]
- Marquina, G.; Waki, H.; Fernandez, L.E.; Kon, K.; Carr, A.; Valiente, O.; Perez, R.; Ando, S. Gangliosides expressed in human breast cancer. Cancer Res. 1996, 56, 5165–5171. [Google Scholar]
- Kong, Y.; Yu, J.; Si, L.; Chi, Z.; Cui, C.; Sheng, X.; Guo, J. Abstract 2303: The expression of gangliosides GD2 is associated with worse prognosis in melanoma patients. Cancer Res. 2016, 76, 2303. [Google Scholar] [CrossRef]
- Roth, M.; Linkowski, M.; Tarim, J.; Piperdi, S.; Sowers, R.; Geller, D.; Gill, J.; Gorlick, R. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 2014, 120, 548–554. [Google Scholar] [CrossRef] [Green Version]
- Schulz, G.; Cheresh, D.A.; Varki, N.M.; Yu, A.; Staffileno, L.K.; Reisfeld, R.A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984, 44, 5914–5920. [Google Scholar]
- Alessandri, G.; Filippeschi, S.; Sinibaldi, P.; Mornet, F.; Passera, P.; Spreafico, F.; Cappa, P.M.; Gullino, P.M. Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res. 1987, 47, 4243–4247. [Google Scholar] [PubMed]
- Sarkar, T.R.; Battula, V.L.; Werden, S.J.; Vijay, G.V.; Ramirez-Peña, E.Q.; Taube, J.H.; Chang, J.T.; Miura, N.; Porter, W.; Sphyris, N.; et al. GD3 Synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene 2015, 34, 2958–2967. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ploessl, C.; Pan, A.; Maples, K.T.; Lowe, D.K. Dinutuximab: An anti-GD2 monoclonal antibody for high-risk neuroblastoma. Ann. Pharmacother. 2016, 50, 416–422. [Google Scholar] [CrossRef] [PubMed]
- Sait, S.; Modak, S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev. Anticancer Ther. 2017, 17, 889–904. [Google Scholar] [CrossRef] [PubMed]
- Jiao, P.; Otto, M.; Geng, Q.; Li, C.; Li, F.; Butch, E.R.; Snyder, S.E.; Zhou, H.; Yan, B. Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct. J. Mater. Chem. B 2016, 4, 513–520. [Google Scholar] [CrossRef] [PubMed]
- Massaad, C.A.; Zhang, G.; Pillai, L.; Azhdarinia, A.; Liu, W.; Sheikh, K.A. Fluorescently-tagged anti-ganglioside antibody selectively identifies peripheral nerve in living animals. Sci. Rep. 2015, 5, 15766. [Google Scholar] [CrossRef] [Green Version]
- Yanagishita, M. Function of proteoglycans in the extracellular matrix. Acta Pathol. Jpn 1993, 43, 283–293. [Google Scholar] [CrossRef]
- Elfenbein, A.; Simons, M. Auxiliary and autonomous proteoglycan signaling networks. Methods Enzymol. 2010, 480, 3–31. [Google Scholar] [CrossRef] [Green Version]
- Wang, S.; Qiu, Y.; Bai, B. The expression, regulation, and biomarker potential of glypican-1 in cancer. Front Oncol. 2019, 9, 614. [Google Scholar] [CrossRef] [Green Version]
- Nikitovic, D.; Berdiaki, A.; Spyridaki, I.; Krasanakis, T.; Tsatsakis, A.; Tzanakakis, G.N. Proteoglycans-biomarkers and targets in cancer therapy. Front Endocrinol. (Lausanne) 2018, 9, 69. [Google Scholar] [CrossRef] [Green Version]
- Fico, A.; Maina, F.; Dono, R. Fine-tuning of cell signaling by glypicans. Cell Mol. Life Sci. 2011, 68, 923–929. [Google Scholar] [CrossRef] [PubMed]
- Filmus, J.; Capurro, M. The role of glypicans in Hedgehog signaling. Matrix Biol. 2014, 35, 248–252. [Google Scholar] [CrossRef] [PubMed]
- Matsuo, I.; Kimura-Yoshida, C. Extracellular distribution of diffusible growth factors controlled by heparan sulfate proteoglycans during mammalian embryogenesis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014, 369. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagarajan, A.; Malvi, P.; Wajapeyee, N. Heparan sulfate and heparan sulfate proteoglycans in cancer initiation and progression. Front Endocrinol. (Lausanne) 2018, 9, 483. [Google Scholar] [CrossRef]
- Sanderson, R.D.; Yang, Y.; Purushothaman, A.; Khotskaya, Y.B.; Ritchie, J.P.; Ramani, V.C. Proteoglycans and cancer. In Cell-Extracellular Matrix Interactions in Cancer; Zent, R., Pozzi, A., Eds.; Springer: New York, NY, USA, 2010; pp. 191–215. [Google Scholar] [CrossRef]
- Nishida, T.; Kataoka, H. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers (Basel) 2019, 11, 1339. [Google Scholar] [CrossRef] [Green Version]
- Szatmari, T.; Otvos, R.; Hjerpe, A.; Dobra, K. Syndecan-1 in cancer: Implications for cell signaling, differentiation, and prognostication. Dis. Markers 2015, 2015, 796052. [Google Scholar] [CrossRef] [Green Version]
- Liu, H.; Li, P.; Zhai, Y.; Qu, C.F.; Zhang, L.J.; Tan, Y.F.; Li, N.; Ding, H.G. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J. Gastroenterol. 2010, 16, 4410–4415. [Google Scholar] [CrossRef]
- Capurro, M.; Wanless, I.R.; Sherman, M.; Deboer, G.; Shi, W.; Miyoshi, E.; Filmus, J. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125, 89–97. [Google Scholar] [CrossRef]
- Libbrecht, L.; Severi, T.; Cassiman, D.; Vander Borght, S.; Pirenne, J.; Nevens, F.; Verslype, C.; van Pelt, J.; Roskams, T. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am. J. Surg. Pathol. 2006, 30, 1405–1411. [Google Scholar] [CrossRef]
- Di Paola, M.; Quarta, A.; Conversano, F.; Sbenaglia, E.A.; Bettini, S.; Valli, L.; Gigli, G.; Casciaro, S. Human hepatocarcinoma cell targeting by glypican-3 ligand peptide functionalized silica nanoparticles: Implications for ultrasound molecular imaging. Langmuir 2017, 33, 4490–4499. [Google Scholar] [CrossRef]
- Shimizu, Y.; Suzuki, T.; Yoshikawa, T.; Endo, I.; Nakatsura, T. Next-Generation Cancer Immunotherapy Targeting Glypican-3. Front Oncol. 2019, 9, 248. [Google Scholar] [CrossRef] [PubMed]
- Kufe, D.W.J.N.R.C. Mucins in cancer: Function, prognosis and therapy. Nat. Rev. Cancer 2009, 9, 874–885. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nath, S.; Mukherjee, P. MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med. 2014, 20, 332–342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaur, S.; Kumar, S.; Momi, N.; Sasson, A.R.; Batra, S.K. Mucins in pancreatic cancer and its microenvironment. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 607–620. [Google Scholar] [CrossRef] [Green Version]
- Tréhoux, S.; Duchêne, B.; Jonckheere, N.; Van Seuningen, I. The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. Biochem. Biophys. Res. Commun. 2015, 456, 757–762. [Google Scholar] [CrossRef]
- Zhou, R.; Curry, J.M.; Roy, L.D.; Grover, P.; Haider, J.; Moore, L.J.; Wu, S.T.; Kamesh, A.; Yazdanifar, M.; Ahrens, W.A.; et al. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: Role in induction of VEGF signaling and angiogenesis. Oncogene 2016, 35, 5608–5618. [Google Scholar] [CrossRef] [Green Version]
- Sahraei, M.; Roy, L.D.; Curry, J.M.; Teresa, T.L.; Nath, S.; Besmer, D.; Kidiyoor, A.; Dalia, R.; Gendler, S.J.; Mukherjee, P. MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene 2012, 31, 4935. [Google Scholar] [CrossRef] [Green Version]
- Grover, P.; Nath, S.; Nye, M.D.; Zhou, R.; Ahmad, M.; Mukherjee, P. SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line. Oncotarget 2018, 9, 6897–6910. [Google Scholar] [CrossRef] [Green Version]
- Muniyan, S.; Haridas, D.; Chugh, S.; Rachagani, S.; Lakshmanan, I.; Gupta, S.; Seshacharyulu, P.; Smith, L.M.; Ponnusamy, M.P.; Batra, S.K. MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Genes Cancer 2016, 7, 110–124. [Google Scholar] [CrossRef] [Green Version]
- Inaguma, S.; Kasai, K.; Ikeda, H. GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin. Oncogene 2010, 30, 714. [Google Scholar] [CrossRef] [Green Version]
- Lakshmanan, I.; Ponnusamy, M.P.; Das, S.; Chakraborty, S.; Haridas, D.; Mukhopadhyay, P.; Lele, S.M.; Batra, S.K. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 2012, 31, 805–817. [Google Scholar] [CrossRef] [Green Version]
- Awaya, H.; Takeshima, Y.; Yamasaki, M.; Inai, K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am. J. Clin. Pathol. 2004, 121, 644–653. [Google Scholar] [CrossRef] [PubMed]
- Situ, D.; Wang, J.; Ma, Y.; Zhu, Z.; Hu, Y.; Long, H.; Rong, T. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med. Oncol. 2011, 28, 596–604. [Google Scholar] [CrossRef] [PubMed]
- Hinoda, Y.; Ikematsu, Y.; Horinochi, M.; Sato, S.; Yamamoto, K.; Nakano, T.; Fukui, M.; Suehiro, Y.; Hamanaka, Y.; Nishikawa, Y.; et al. Increased expression of MUC1 in advanced pancreatic cancer. J. Gastroenterol. 2003, 38, 1162–1166. [Google Scholar] [CrossRef] [PubMed]
- Streppel, M.M.; Vincent, A.; Mukherjee, R.; Campbell, N.R.; Chen, S.H.; Konstantopoulos, K.; Goggins, M.G.; Van Seuningen, I.; Maitra, A.; Montgomery, E.A. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum. Pathol. 2012, 43, 1755–1763. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rabassa, M.E.; Croce, M.V.; Pereyra, A.; Segal-Eiras, A. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): A multivariate analysis. BMC Cancer 2006, 6, 253. [Google Scholar] [CrossRef] [Green Version]
- Kannan, A.; Hertweck, K.L.; Philley, J.V.; Wells, R.B.; Dasgupta, S. Genetic Mutation and exosome signature of human papilloma virus associated oropharyngeal cancer. Sci. Rep. 2017, 7, 46102. [Google Scholar] [CrossRef]
- Sato, S.; Kato, T.; Abe, K.; Hanaoka, T.; Yano, Y.; Kurosaki, A.; Yasuda, M.; Sekino, T.; Fujiwara, K.; Hasegawa, K. Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression. Oncol. Lett. 2017, 14, 776–786. [Google Scholar] [CrossRef]
- Peters, I.T.; Hilders, C.G.; Sier, C.F.; Vahrmeijer, A.L.; Smit, V.T.; Baptist Trimbos, J.; Kuppen, P.J. Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue. Arch. Gynecol. Obstet. 2016, 294, 385–393. [Google Scholar] [CrossRef] [Green Version]
- Heublein, S.; Friese, K.; Kost, B.; Marmé, F.; Kuhn, C.; Mahner, S.; Dannecker, C.; Mayr, D.; Jeschke, U.; Vattai, A. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer. J. Cancer Res. Clin. Oncol. 2018, 144, 1899–1907. [Google Scholar] [CrossRef]
- Ginath, S.; Menczer, J.; Fintsi, Y.; Ben-Shem, E.; Glezerman, M.; Avinoach, I. Tissue and serum CA125 expression in endometrial cancer. Int. J. Gynecol. Cancer. 2002, 12, 372–375. [Google Scholar] [CrossRef] [PubMed]
- Fan, X.N.; Karsten, U.; Goletz, S.; Cao, Y. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol. Res. Pract. 2010, 206, 585–589. [Google Scholar] [CrossRef] [PubMed]
- Dian, D.; Lenhard, M.; Mayr, D.; Heublein, S.; Karsten, U.; Goletz, S.; Kuhn, C.; Wiest, I.; Friese, K.; Weissenbacher, T.; et al. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol. Histopathol. 2013, 28, 239–244. [Google Scholar] [CrossRef] [PubMed]
- Fiedler, W.; DeDosso, S.; Cresta, S.; Weidmann, J.; Tessari, A.; Salzberg, M.; Dietrich, B.; Baumeister, H.; Goletz, S.; Gianni, L.; et al. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. Eur. J. Cancer 2016, 63, 55–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gold, D.V.; Lew, K.; Maliniak, R.; Hernandez, M.; Cardillo, T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int. J. Cancer 1994, 57, 204–210. [Google Scholar] [CrossRef]
- Gold, D.V.; Karanjawala, Z.; Modrak, D.E.; Goldenberg, D.M.; Hruban, R.H. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin. Cancer Res. 2007, 13, 7380–7387. [Google Scholar] [CrossRef] [Green Version]
- Berek, J.S.; Taylor, P.T.; Gordon, A.; Cunningham, M.J.; Finkler, N.; Orr, J., Jr.; Rivkin, S.; Schultes, B.C.; Whiteside, T.L.; Nicodemus, C.F. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. 2004, 22, 3507–3516. [Google Scholar] [CrossRef]
- Kudelka, M.R.; Ju, T.; Heimburg-Molinaro, J.; Cummings, R.D. Simple sugars to complex disease--mucin-type O-glycans in cancer. Adv. Cancer Res. 2015, 126, 53–135. [Google Scholar] [CrossRef] [Green Version]
- Stowell, S.R.; Ju, T.; Cummings, R.D. Protein glycosylation in cancer. Annu. Rev. Pathol. 2015, 10, 473–510. [Google Scholar] [CrossRef] [Green Version]
- Fuster, M.M.; Esko, J.D. The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5, 526–542. [Google Scholar] [CrossRef]
- Lebrilla, C.B.; An, H.J. The prospects of glycan biomarkers for the diagnosis of diseases. Mol. Biosyst. 2009, 5, 17–20. [Google Scholar] [CrossRef] [PubMed]
- Tang, H.; Singh, S.; Partyka, K.; Kletter, D.; Hsueh, P.; Yadav, J.; Ensink, E.; Bern, M.; Hostetter, G.; Hartman, D.; et al. Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A. Mol. Cell Proteomics 2015, 14, 1323–1333. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tang, Y.; Cui, Y.; Zhang, S.; Zhang, L. Chapter five–The sensitivity and specificity of serum glycan-based biomarkers for cancer detection. Prog. Mol. Biol. Transl. Sci. 2019, 162, 121–140. [Google Scholar] [CrossRef] [PubMed]
- Tommasone, S.; Allabush, F.; Tagger, Y.K.; Norman, J.; Köpf, M.; Tucker, J.H.R.; Mendes, P.M. The challenges of glycan recognition with natural and artificial receptors. Chem. Soc. Rev. 2019, 48, 5488–5505. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechn. 2005, 23, 1147–1157. [Google Scholar] [CrossRef]
- Eisen, H.N. Affinity enhancement of antibodies: How low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses. Cancer Immunol. Res. 2014, 2, 381–392. [Google Scholar] [CrossRef] [Green Version]
- Cao, Y.; Lan, Y.; Qian, J.; Zheng, Y.; Hong, S.; Li, H.; Wang, M.; Kwak, L.W.; Lin, D.; Yang, J.; et al. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br. J. Haematol. 2011, 154, 111–121. [Google Scholar] [CrossRef] [Green Version]
- Manimala, J.C.; Roach, T.A.; Li, Z.; Gildersleeve, J.C. High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 2007, 17, 17–23. [Google Scholar] [CrossRef]
- Sterner, E.; Flanagan, N.; Gildersleeve, J.C. Perspectives on anti-glycan antibodies gleaned from development of a community resource database. ACS Chem. Biol. 2016, 11, 1773–1783. [Google Scholar] [CrossRef]
- Cummings, R.D.; Darvill, A.G.; Etzler, M.E.; Hahn, M.G. Glycan-recognizing probes as tools. In Essentials of Glycobiology; Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., Prestegard, J.H., Eds.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor: New York, NY, USA, 2015; pp. 611–625. [Google Scholar] [CrossRef]
- Heijs, B.; Holst-Bernal, S.; de Graaff, M.A.; Briaire-de Bruijn, I.H.; Rodriguez-Girondo, M.; van de Sande, M.A.J.; Wuhrer, M.; McDonnell, L.A.; Bovée, J. Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging. Lab. Invest. 2020. [Google Scholar] [CrossRef]
- Liu, Y.; Wang, C.; Wang, R.; Wu, Y.; Zhang, L.; Liu, B.F.; Cheng, L.; Liu, X. Isomer-specific profiling of N-glycans derived from human serum for potential biomarker discovery in pancreatic cancer. J. Proteomics 2018, 181, 160–169. [Google Scholar] [CrossRef] [PubMed]
- Gebrehiwot, A.G.; Melka, D.S.; Kassaye, Y.M.; Gemechu, T.; Lako, W.; Hinou, H.; Nishimura, S.-I. Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women. BMC Cancer 2019, 19, 588. [Google Scholar] [CrossRef] [PubMed]
- Oikawa, M.; Hatakeyama, S.; Yoneyma, T.; Tobisawa, Y.; Narita, T.; Yamamoto, H.; Hashimoto, Y.; Koie, T.; Narita, S.; Sasaki, A.; et al. Significance of serum N-glycan profiling as a diagnostic biomarker in urothelial carcinoma. Eur. Urol. Focus 2018, 4, 405–411. [Google Scholar] [CrossRef] [PubMed]
- Gersten, K.M.; Natsuka, S.; Trinchera, M.; Petryniak, B.; Kelly, R.J.; Hiraiwa, N.; Jenkins, N.A.; Gilbert, D.J.; Copeland, N.G.; Lowe, J.B. Molecular cloning, expression, chromosomal assignment, and tissue-specific expression of a murine alpha-(1,3)-fucosyltransferase locus corresponding to the human ELAM-1 ligand fucosyl transferase. J. Biol. Chem. 1995, 270, 25047–25056. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Preclinical Studies | |||||||
---|---|---|---|---|---|---|---|
Target | Targeting Moiety | Appl. | Conjugate | Cancer Type | Cell Line | Mouse Model or Phase | Reference |
Thomsen-Friedenreich | PNA-coated nano-beacon | FI | Coumarin 6 | Colon | HCT 116 | Subcutaneous | [11] |
TF peptide | PET | 64Cu-NO2A | Breast | MDA-MB-435 | Subcutaneous | [12] | |
A38C tetramer | NIRF | AF647 | Ovarian Peritoneal Carcinomatosis | IGROV-1 | Orthotopic | [13] | |
Thomsen-Nouveau | 2154F12A4 mAb | NIRF | Qdot-800 | Breast | MCF7 | Subcutaneous | [14] |
sialyl-Thomsen-Nouveau | 3E8 scFv | NIRF | IRDye 800 | Colon | LS174T | Orthotopic | [15] |
CC49 mAb HuCC49ΔCH2 mAb | NIRF | Cy7 | Colon | LS174T | Subcutaneous | [16] | |
HuCC49ΔCH2 | PET | 124I-DOTA | Colon | LS174T | Subcutaneous | [17] | |
Pre-target: CC49-HaloTag | SPECT | 111In-HaloTag ligands | Colon | LS174T | Subcutaneous | [18] | |
HuCC49ΔCH2 | SPECT/γ-scin | 111In | Colon | LS174T | Subcutaneous | [19] | |
CC49 mAb-benzamide-TCO | SPECT/γ-scin | 111In-Tz | Colon | LS174T | Subcutaneous | [20] | |
CC49 mAb-acetamide-TCO | SPECT/γ-scin | 111In-Tz | Colon | LS174T | Subcutaneous | [21] | |
Lewisa/c/x | CH88.2 | NIRF | IRDye 800CW | Colon, Pancreas | HT-29, BxPC-3 | Subcutaneous | [22] |
sialyl-Lewisa | Anti-CA19-9 mAb | FI | AF488 dye | Pancreas | BxPC-3 | Subcutaneous, orthotopic | [23] |
Anti-CA 19-9 mAb | FI | DyLight 650 | Pancreas | PDOX | Orthotopic | [24] | |
Anti-CA19-9 diabody | PET | 124I | Pancreas | BxPc-3, Capan-2, MIA PaCa-2 | Subcutaneous | [25] | |
Anti-CA19-9 cys- diabody | PET | 124I | Pancreas | BxPC-3 | Subcutaneous | [26] | |
HuMAb-5B1 mAb | PET | 89Zr-DFO123456 | Bladder | HT 1197 | Subcutaneous | [27] | |
Pre-targeted: 5B1 mAb | PET | 89Zr | Pancreas | Capan-2 | Subcutaneous, orthotopic | [28] | |
5B1 mAb-TCO | PET | 64Cu-NOTA-PEG7-Tz | Pancreas | BxPC-3, Capan-2 | Subcutaneous, orthotopic | [29] | |
PEGPH20 and HuMab-5B1 mAb | PET | 89Zr-DFO | Pancreas | BxPC3-HAS3 | Subcutaneous | [30] | |
5B1 mAb | PET/NIRF | 89Zr-DFO FL dye | Pancreas | BxPC-3, MIA PaCa-2, Suit-2 | Subcutaneous, orthotopic | [31] | |
sialyl-Lewisx | sLeX-carrying liposomes | NIRF | Cy5.5 | - | Ehrlich Ascites tumor | Subcutaneous | [32] |
Lewisy | hu3S193 mAb | PET SPECT/γ-scin | 111In, 86Y | Colon | HCT-15 | Subcutaneous | [33] |
hu3S193 diabody F(ab’)2 | SPECT/γ-scin | 111In-CHX-A”-DTPA | Breast | MCF-7 | Subcutaneous | [34] | |
GD2 | ch14.18-CHO | NIRF | IRDye 800CW | Neuroblastoma | KCNR, patient-derived | Orthotopic | [35] |
hu14.18K322A mAb | PET | 64Cu-p-NH2-Bn-DOTA | Neuroblastoma, melanoma | M21, PC-3. | Subcutaneous | [36] | |
hu14.18K322A mAb | PET | 64Cu-Bn-NOTA | Osteosarcoma | SJOS072 | Subcutaneous | [37] | |
Syndecan-1 | Recombinant syndecan-1 | MSOT | CF750 succinyl ester | Pancreas | S2VP10 | Orthotopic | [38] |
9E7.4 mAb | PET | 64Cu-TE2A | Multiple myeloma | 5T33 | Subcutaneous, orthotopic | [39] | |
Glypican-1 | Glypican-1 mAb | FI/MRI | Gd-Au-nanoclusters | Pancreas | COLO-357 | Subcutaneous | [40] |
Glypican-3 | Pretarget: L5 peptide | MRI | SA-PEG-USPIO | HCC | HepG2 | Subcutaneous | [41] |
TJ12P1 peptide | NIRF | Cy5.5 | HCC, Prostate | HepG2, PC3 | Subcutaneous | [42] | |
αGPC3 mAb | PET | 89Zr | HCC | HepG2 | Orthotopic | [43] | |
αGPC3 F(ab’)2 | PET | 89Zr | HCC | HepG2 | Orthotopic | [44] | |
MUC1 | EPPT peptide | MRI/NIRF | Magnetic NP-Cy5.5 | Colon | MC38 MUC1 | Orthotopic | [45] |
EPPT peptide | MRI/NIRF | Magnetic NP-Cy5.5 | Breast | Spontaneous | Orthotopic | [46] | |
EPPT peptide | MRI/NIRF | Magnetic NP-Cy5.5 | Pancreas | Spontaneous | Orthotopic | [47] | |
EPPT peptide | MRI/NIRF | Magnetic NP-Cy5.5 | Colon | LS174T | Subcutaneous | [48] | |
CT2 mAb | NIRF | DyLight 650 | Pancreas | Panc-1, BxPC-3 | Subcutaneous, orthotopic | [49] | |
hMUC1 mAb | NIRF | DyLight 755 | Pancreas | Capan-2 | Subcutaneous | [50] | |
CD227 mAb | NIRF | Fluorescein-Cy5.5 | Ovary | OVCAR3 | Subcutaneous | [51] | |
MUC1 aptamer | NIRF | MPA-PEG | Breast, liver | MCF-7, HepG2 | Subcutaneous | [52] | |
TAB 004 mAb | NIRF | ICG | Breast | PyMT, MMT, spontaneous | Orthotopic | [53] | |
GGSK-1/30 | PET/MRI | 89Zr | Breast | PyMTxhuMUC1 | Subcutaneous | [54] | |
PR81 mAb | PET/SPECT | 64Cu-DOTA | Breast | MCF-7 | Subcutaneous | [55] | |
PR81 mAb | SPECT/γ-scin | 99mTc | Breast | Spontaneous | Orthotopic | [56] | |
MUC1/MUC5AC | Pretarget: TF10 bispecific mAb | γ-scin | 125I-IMP-288 | Pancreas | Capan-1 | Subcutaneous | [57] |
bsPAM4 F(ab’)2 | γ-scin | 125I | Pancreas | Capan-1 | Subcutaneous | [58] | |
Pretarget: bsPAM4 F(ab’)2 | γ-scin | 111In-IMP-156 99mTc-IMP-192 | Pancreas | Capan-1 | Subcutaneous | [58] | |
MUC5AC | 60C peptide | MRI | USPIO | Colon | HT-29, HCT 116 | Subcutaneous | [59] |
MUC16 | AR9.6 mAb | NIRF | IRDye 800CW | Pancreas | COLO 357, T3M4 | Subcutaneous, orthotopic | [60] |
B43.13 mAb B43.13 scFv | PET | 64Cu | Ovary | OVCAR3, SKOV3 | Subcutaneous | [61] | |
B43.13 mAb | PET | 89Zr | Ovary | OVCAR3, SKOV3 | Subcutaneous | [62] | |
B43.13 mAb B43.13 scFv | PET | 18F (FBz) | Ovary | OVCAR3, SKOV3 | Subcutaneous | [63] | |
Clinical Studies | |||||||
sialyl-Thomsen-Nouveau | B72.3 mAb | RIGS | 125I | Colon, rectum | - | Phase 1/2 | [64] |
CC49 mAb | RIGS | 125I | Colon, rectum | - | Phase 1 | [65] | |
CC49 mAb | RIGS | 125I | Colon, rectum | - | Phase 1 | [66] | |
HuCC49ΔCH2 mAb | RIGS | 125I | Colon, rectum | - | Phase 1 | [67] | |
HuCC49ΔCH2 mAb | RIGS | 125I | Colon, rectum | - | Phase 1 | [68] | |
sialyl-Lewisa | HuMAb-5B1 mAb | PET | 89Zr-DFO | Pancreas | - | Phase 1 | [69] |
B3 mAb | SPECT | 111In | Various | - | Phase 1 | [70] | |
Lewisy | hu3S193 mAb | SPECT/γ-scin | 111In | Lung | - | Phase 1 | [71] |
GD2 | ch14.18 mAb | γ-scin | 99mTc | Neuroblastoma | - | Phase 1 | [72] |
3F8 mAb | γ-scin | 131I | Neuroblastoma | - | Phase 1 | [73] | |
3F8 mAb | PET | 124I | Neuroblastoma | - | Case report | [74] | |
MUC1 | C595 mAb | γ-scin | 111In | Bladder | - | Phase 1 | [75] |
C595 mAb | γ-scin | 99mTc | Bladder | - | Phase 1 | [76] | |
MUC1/MUC5AC | hPAM4 mAb | γ-scin | 111In | Pancreas | - | Phase 1 | [77] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Houvast, R.D.; Vankemmelbeke, M.; Durrant, L.G.; Wuhrer, M.; Baart, V.M.; Kuppen, P.J.K.; de Geus-Oei, L.-F.; Vahrmeijer, A.L.; Sier, C.F.M. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers 2020, 12, 3870. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12123870
Houvast RD, Vankemmelbeke M, Durrant LG, Wuhrer M, Baart VM, Kuppen PJK, de Geus-Oei L-F, Vahrmeijer AL, Sier CFM. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers. 2020; 12(12):3870. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12123870
Chicago/Turabian StyleHouvast, Ruben D., Mireille Vankemmelbeke, Lindy G. Durrant, Manfred Wuhrer, Victor M. Baart, Peter J. K. Kuppen, Lioe-Fee de Geus-Oei, Alexander L. Vahrmeijer, and Cornelis F. M. Sier. 2020. "Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging" Cancers 12, no. 12: 3870. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12123870